NCT01333449View on ClinicalTrials.gov

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Decitabine

20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.

Trial Locations (1)

169608

Singapore General Hospital, Singapore

Sponsors

Collaborators (1)

Johnson & Johnson

All Listed Sponsors

collaborator

Johnson & Johnson

INDUSTRY

lead

Singapore General Hospital

OTHER